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Abstract: Cells possess the capability to adjust their volume for various physiological processes,
presumably including cell proliferation and migration. The volume-regulated anion channel (VRAC),
formed by LRRC8 heteromers, is critically involved in regulatory volume decrease of vertebrate cells.
The VRAC has also been proposed to play a role in cell cycle progression and cellular motility. Indeed,
recent reports corroborated this notion, with potentially important implications for the VRAC in
cancer progression. In the present study, we examined the role of VRAC during cell proliferation and
migration in several cell types, including C2C12 myoblasts, human colon cancer HCT116 cells, and
U251 and U87 glioblastoma cells. Surprisingly, neither pharmacological inhibition of VRAC with
4-[(2-Butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1H-inden-5-yl)oxy]butanoic acid (DCPIB),
carbenoxolone or 5-nitro-2-(3-phenylpropyl-amino)benzoic acid (NPPB), nor siRNA-mediated
knockdown or gene knockout of the essential VRAC subunit LRRC8A affected cell growth and
motility in any of the investigated cell lines. Additionally, we found no effect of the VRAC inhibition
using siRNA treatment or DCPIB on PI3K/Akt signaling in glioblastoma cells. In summary, our work
suggests that VRAC is dispensable for cell proliferation or migration.
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1. Introduction
The volume-regulated anion channel (VRAC), alternatively named the volume-sensitive outwardly
rectifying (VSOR) anion channel, is ubiquitously expressed in almost all vertebrate cells [1–3]. The
VRAC is formed by heteromers of LRRC8 proteins, with LRRC8A being the only essential subunit which
has to combine with at least one other LRRC8 member (B–E) [4–6]. The channel opens upon osmotic cell
swelling and contributes to regulatory volume decrease (RVD) by releasing chloride ions and various
organic osmolytes [1–3,7–9]. The VRAC is additionally involved in further processes beyond RVD,
such as cancer drug uptake [10], insulin secretion [11,12], astrocyte-neuron communication [13–15],
and sperm development [16].
During cell proliferation, the transient activation of Cl− channels leads to a decrease in cell
volume after an initial volume increase [17–19]. Cell migration is mainly mediated by cytoskeletal
rearrangements and directed membrane transport. In addition, osmotic water flux by the differential
activity of ion channels and transporters mediating local changes in cell volume was found to contribute
to cell movement [20,21]. The uptake of inorganic ions and water (a regulatory volume increase, RVI)
at the leading edge by locally active Na+-K+-2Cl− cotransport, Na+/H+ exchange or nonselective cation
channels, and a volume decrease at the trailing end via release of K+ and Cl− through activated K+ and
Cl− channels followed by water eﬄux (RVD) will lead to a net translocation of the cell [22]. Recently,
cell displacement was found to be solely driven by directed cellular osmotic water transport in an
artificial confined environment when actin polymerization was inhibited [23].
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Due to its role in regulatory volume decrease, the VRAC has been proposed to be involved in cell
volume changes during cell proliferation and migration [17,22,24–26]. Consistently, maximal VRAC
currents were found to change during cell cycle progression [27]. Indeed, various (rather unspecific)
VRAC inhibitors were reported to impair the proliferation rate of a wide range of cell types [28–38].
Glycine-induced cell swelling, on the other hand, was correlated with the migration of microglial
cells [39]. The motility of nasopharyngeal carcinoma and glioma cells was reported to be suppressed by
VRAC inactivation with pharmacological inhibitors or hypertonic solution. [24,25]. More recently, the
VRAC inhibitor 4-[(2-Butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1H-inden-5-yl)oxy]butanoic
acid (DCPIB) was shown to reduce the migration of glioblastoma cell lines [28]. The siRNA-mediated
knockdown of the obligate VRAC subunit LRRC8A was reported to limit the proliferation of
glioblastoma cells [40] and reduce the migration of human colon cancer HCT116 cells [41].
However, several observations cast doubt on a general role for the VRAC in cell proliferation
and migration. So far, no proliferation defect has been reported for any of the various published
LRRC8A-deficient cells lines. The proliferation of HeLa cells was reported to be unaffected by the
siRNA-mediated knockdown of LRRC8A [42]. Recently, the flavonoid Dh-morin was shown to
effectively inhibit endogenous VRAC currents in endothelial cells, without impairing the proliferation
of human umbilical vein endothelial (HUVEC) cells [43], arguing against a crucial role for the VRAC in
the cell cycle progression of this cell type. The anti-proliferative effect of submicromolar concentrations
of cardiac glycosides was even linked, albeit not necessarily directly, to an increase of VRAC activity in
HT-29 colorectal cancer cells and could be blocked by the VRAC inhibitor DCPIB [44].
In all, there are conflicting data as to the role of VRAC in cell proliferation and migration.
To study the potential role of VRAC in cell proliferation and migration, and therefore we systematically
examined these processes for a variety of cell lines, including cancer and noncancer cell lines, by
using pharmacological blockers, siRNA against LRRC8A, and genomic VRAC knockout. In none of
the studied cell lines did we find evidence for a critical involvement of VRAC in cell proliferation
or migration.
2. Results
2.1. LRRC8A Knockout Does Not Impinge on the Proliferation and Migration of C2C12 Cells
To investigate the putative role of the VRAC in the proliferation and migration of C2C12 mouse
myoblast cells, we used various clonal genome-edited cell lines deficient for the essential VRAC
subunit LRRC8A (clones 27, 13, and 14) and a line (clone 4) with only heterozygous LRRC8A deletion
that had experienced the same transfection and selection process as the knockout clones. The loss of
LRRC8A in the knockout clones and reduced levels in clone 4 in comparison to wild-type C2C12 cells
was confirmed by Western blotting (Figure 1A). We first assessed the effects of LRRC8A knockout on
C2C12 proliferation. The proliferation rate of the knockout clones was similar to that of wild-type
cells or the heterozygous clone (Figure 1B), demonstrating that VRAC is dispensable for C2C12 cell
proliferation. Next, we investigated the role of LRRC8A in cell migration using a wound healing
assay (Figure 1C,D). We observed no significant differences in migration speed among LRRC8A
knockout (clone 27, 26.22 ± 2.15 µm/h; clone 13, 23.91 ± 2.36 µm/h; clone 14, 27.79 ± 4.77 µm/h),
the heterozygous cells (clone 4, 26.98 ± 3.33 µm/h) and wild-type C2C12 cells (26.49 ± 2.70 µm/h).
These results demonstrate that LRRC8A, and hence VRAC activity, plays no important role in C2C12
migration in the wound healing assay.
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Figure 1. LRRC8A depletion does not affect C2C12 cell proliferation and migration. (A) Protein levels 
of LRRC8A in wild-type (WT), LRRC8A-knockout (KO) and heterozygous (Het) C2C12 cells tested 
by Western blotting. GAPDH used as loading control. A representative blot of three independent 
experiments is shown. (B) Growth curve of WT, KO, and Het C2C12 cells. Data represent mean ± SD 
of n = 4 experiments. (C) Representative images of the wound healing assay with C2C12 cells at 
indicated time points. Initial wound mark depicted in blue, cells in orange on blue overlay represents 
migrated cells. Scale bar, 400 μm. (D) Quantification of migration speed of C2C12 cells. Cell migration 
speed was determined 14 h post-wounding. Data represent mean ± SD of n = 14 experiments. 
2.2. VRAC Blockers and Disruption of LRRC8s do not Impair HCT 116 Proliferation and Migration 
Since the involvement of ion channels in cell growth and migration is of particular interest in 
relation to cancer progression [45–48], we investigated a potential role of VRAC in the proliferation 
and migration of human colon cancer HCT116 cells. We first examined the effects of genomic VRAC 
knockout on HCT116 proliferation (Figure 2A). Although the proliferation of genomic VRAC 
knockout clones seemed slightly decreased as compared with wild-type cells during the first 48 h, 
the proliferation of a clonal cell line lacking the essential LRRC8A subunit of VRAC was virtually 
equal to that of wild-type cells over the complete time course. Another clonal cell line, lacking all five 
LRRC8 members, even displayed an increase in proliferation. These results demonstrate that VRAC 
is not critically involved in HCT116 proliferation. Next, we examined the effect of the genomic VRAC 
deletion and of the VRAC inhibitor carbenoxolone (CBX) on HCT116 cell motility in our wound 
healing assay (Figure 2B). Neither pharmacological inhibition of VRAC with up to 50 μM CBX, nor 
gene knockout of VRAC affected motility of the HCT116 cells. Together, these data demonstrate that 
VRAC is dispensable for human colon cancer proliferation and migration. 
Figure 1. LRRC8A depletion does not affect C2C12 cell proliferation and migration. (A) Protein levels
of LR C8A in wild-type (WT), LR C8A-knockout (KO) and heterozygous (Het) C2C12 cells tested
by Western blotting. GAPDH used as loading control. A representative blot of thre independent
experiments is hown. (B) Growth curve of WT, KO, and Het C2 12 cells. Data rep sent mean ± SD of
n = 4 experiments. (C) Representative images of the wound heali g ass y with C2C12 cells at indicated
time points. Initial wound mark depicted in blue, cells in orange o blue overlay r presents migrated
cells. Scale bar, 400 µm. (D) Quantification of migration speed of C2C12 cells. Cell migration speed
was determin d 14 h post-wounding. Data represent m an ± SD of n = 14 experiments.
2.2. VRAC Blockers and Disruption of LRRC8s Do Not Impair HCT 116 Proliferation and Migration
Since the involvement of ion channels in cell growth and migration is of particular interest in
relation to cancer progression [45–48], we investigated a potential role of VRAC in the proliferation
and migration of human colon cancer HCT116 cells. We first examined the effects of genomic VRAC
knockout on HCT116 proliferation (Figure 2A). Although the proliferation of genomic VRAC knockout
clones seemed slightly decreased as compared with wild-type cells during the first 48 h, the proliferation
of a clonal cell line lacking the essential LRRC8A subunit of VRAC was virtually equal to that of
wild-type cells over the complete time course. Another clonal cell line, lacking all five LRRC8 members,
even displayed an increase in proliferation. These results demonstrate that VRAC is not critically
involved in HCT116 proliferation. Next, we examined the effect of the genomic VRAC deletion and
of the VRAC inhibitor carbenoxolone (CBX) on HCT116 cell motility in our wound healing assay
(Figure 2B). Neither pharmacological inhibition of VRAC with up to 50 µM CBX, nor gene knockout of
VRAC affected motility of the HCT116 cells. Together, these data demonstrate that VRAC is dispensable
for human colon cancer proliferation and migration.
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Figure 2. Effect of LRRC8 subunit knockout or carbenoxolone (CBX) treatment on cell proliferation 
and migration of HCT116 cells. (A) Growth curve of wild-type (WT), LRRC8A-knockout (KO), and 
LRRC8A~E-knockout (KO) HCT116 cells. Data represent mean ± SD of n = 6–9 experiments. Inset: 
Knockout of the LRRC8A subunit was confirmed by Western blotting. (B) Effect of LRRC8 subunits 
knockout or treatment with CBX on migration of HCT116 cells. Cell migration speed was determined 
24 h post-wounding. Data represent mean ± SD of n = 7 experiments. 
2.3. LRRC8A/VRAC is not Required for the Proliferation and Migration of Glioblastoma Cells 
While VRAC plays no important role in HCT116 cell proliferation and migration, the 
contribution of VRAC to cell proliferation and migration may vary between cell types. Glioblastoma 
multiforme (GBM) is a common, rapidly growing malignant brain tumor [49,50]. To examine the 
contribution of VRAC to GBM cell proliferation and migration, we first assessed the effects of 
pharmacological inhibitors on the established glioblastoma cell lines U251 and U87 (Figure 3). 
Treatment with up to 100 μM CBX did not alter the proliferation rate of U251 or 87 cells (Figure 3A,B). 
Consistently, proliferation was neither affected by VRAC inhibition with up to 100 μM DCPIB (Figure 
3C,D). Next, we tested the effect of the VRAC inhibitors on GBM cell migration in the wound healing 
assay. We observed no significant differences in migration speed between inhibitor-treated and 
control U251 and U87 cells (Figure 3E,F). Collectively, these results suggest that VRAC activity is 
dispensable for GBM cell proliferation and 2D migration. 
Figure 2. Effect of LRRC8 subunit knockout or carbenoxolone (CBX) treatment on cell proliferation
and migration of HCT116 cells. (A) Growth curve of wild-type (WT), LRRC8A-knockout (KO), and
LRRC8A~E-knockout (KO) HCT116 cells. Data represent mean ± SD of n = 6–9 experiments. Inset:
Knockout of the LRRC8A subunit was confirmed by Western blotting. (B) Effect of LRRC8 subunits
knockout or treatment with CBX on migration of HCT116 cells. Cell migration speed was determined
24 h post-wounding. Data represent mean ± SD of n = 7 experiments.
2.3. LRRC8A/VRAC Is Not Required for the Proliferation and Migration of Glioblastoma Cells
While VRAC plays no important role in HCT116 cell proliferation and migration, the contribution
of VRAC to cell proliferation and migration may vary between cell types. Glioblastoma multiforme
(GBM) is a common, rapidly growing malignant brain tu or [49,50]. To examine the contribution
of VRAC to GBM cell proliferation and migration, we first assessed the effects of pharmacological
inhibitors on the established glioblastoma cell lines U251 and U87 (Figure 3). Treatment with up
to 100 µM CBX did not alter the proliferation rate of U251 or 87 cells (Figure 3A,B). Consistently,
proliferation was neither affected by VRAC inhibition with up to 100 µM DCPIB (Figure 3C,D). Next,
we tested the effect of the VRAC inhibitors on GBM cell migration in the wound healing assay. We
observed no significant differences in migration speed between inhibitor-treated and control U251 and
U87 cells (Figure 3E,F). Collectively, these results suggest that VRAC activity is dispensable for GBM
cell proliferation and 2D migration.
Since these data are in apparent conflict with the previously reported effect of DCPIB on GBM cell
migration [28], we additionally approached the role of VRAC by silencing the expression of the essential
VRAC subunit LRRC8A with siRNA. Western blotting confirmed a robust reduction of LRRC8A protein
amount after transfection with siRNA against LRRC8A for 48 or 72 h in U251 and U87 cells at two days
(by roughly 40% and 30%, respectively) and three days (by roughly 70%) after transfection with siRNA
against LRRC8A (Figure 4A–D) cells. Proliferation of both cell lines, assessed from 48 h after siRNA or
control transfection onwards, was not affected by the LRRC8A knockdown. In the wound healing
assay, also started 48 h after transfection, we observed no significant differences in the migration speed
between non-transfected cell, cells transfected with control siRNA, and cells transfected with siRNA
against LRRC8A at various time points after transfection (Figure 4G,H, Figure S1).
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Figure 3. Volume-regulated anion channel (VRAC) blockers do not affect proliferation and migration 
of glioblastoma multiforme (GBM) cells. Growth curve of U251 (A, C) and U87 (B, D) after treatment 
with indicated concentrations of CBX (A, B) or DCPIB (C, D). Data represent mean ± SD of n = 3–7 
experiments. Cell migration of U251 (E) and U87 (F) after treatment with indicated concentrations of 
CBX, NPPB or DCPIB. The diagonal lines represent controls. Data represent mean ± SD of n = 4–10 
experiments. 
Figure 3. Volume-regulated anion channel (VRAC) blockers do not affect proliferation and migration of
glioblastoma multiforme (GBM) cells. Growth curve of U251 (A,C) and U87 (B,D) after treatment with
indicated concentrations of CBX (A,B) or DCPIB (C,D). Data represent mean± SD of n = 3–7 experiments.
Cell migration of U251 (E) and U87 (F) after treatment with indicated concentrations of CBX, NPPB or
DCPIB. The diagonal lines represent controls. Data represent mean ± SD of n = 4–10 experiments.
Together, these results from pharmacological VRAC inhibition and LRRC8A knockdown suggest
that VRAC is dispensable for glioblastoma cell proliferation and migration in the wound healing assay.
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Figure 4. Downregulation of LRRC8A does not affect GBM cell growth and motility. Expression of 
LRRC8A protein significantly decreased after U251 (C) and U87 (D) cells transfected with siRNA 
against LRRC8A for 48 h and 72 h. ** p < 0.01, *** p < 0.001 vs. scrambled. Data represent mean ± SD 
from n = 3 independent experiments. GAPDH on the same blot was used as an internal control. 
Representative blots of three independent experiments for U251 (A) and U87 (B) were shown. 
Proliferation of U251 (E) and U87 (F) started 48 h after transfection with siRNA against LRRC8A. Data 
represent mean ± SD of n = 8 experiments. (G) U251 cell migration started after 48 h transfection with 
siRNA against LRRC8A. The data were calculated after cell migrated for 24 h. Data represent mean ± 
SD of n = 5 experiments. (H) U87 cell migration started after 48 h transfection with siRNA against 
LRRC8A. Note the high values due to absence of mitomycin in the wound healing assay in this case. 
The data were calculated after cell migrated for 14 h. Data represent mean ± SD of n = 7 experiments. 
Since these data are in apparent conflict with the previously reported effect of DCPIB on GBM 
cell migration [28], we additionally approached the role of VRAC by silencing the expression of the 
essential VRAC subunit LRRC8A with siRNA. Western blotting confirmed a robust reduction of 
LRRC8A protein amount after transfection with siRNA against LRRC8A for 48 or 72 h in U251 and 
Figure 4. Downregulation of LRRC8A does not affect GBM cell growth and motility. Expression of
LRRC8A protein significantly decreased after U251 (C) and U87 (D) cells transfected with siRNA against
LRRC8A for 48 h and 72 h. ** p < 0.01, *** p < 0.001 vs. scrambled. Data represent mean ± SD from n = 3
independent experiments. GAPDH on the same blot was used as an internal control. Representative
blots of three independent experiments for U251 (A) and U87 (B) were shown. Proliferation of U251
(E) and U87 (F) started 48 h after transfection with siRNA against LRRC8A. Data represent mean ±
SD of n = 8 experiments. (G) U251 cell migration started after 48 h transfection with siRNA against
LRRC8A. The data were calculated after cell migrated for 24 h. Data represent mean ± SD of n = 5
experiments. (H) U87 cell migration started after 48 h transfection with siRNA against LRRC8A. Note
the high values due to absence of mitomycin in the wound healing assay in this case. The data were
calculated after cell migrated for 14 h. Data represent mean ± SD of n = 7 experiments.
Int. J. Mol. Sci. 2019, 20, 2663 7 of 14
2.4. VRAC Inhibition by DCPIB or LRRC8A Downregulation Does Not Affect PI3K/Akt Signaling in
GBM Cells
Since activation of mTOR signaling by the PI3K/Akt pathway is involved in the regulation of GBM
cell proliferation and migration [51–53], we examined whether VRAC is involved in PI3K/Akt/mTOR
signaling. To this end, we assessed the phosphorylation status of Akt and the mTOR substrate ULK
by Western blotting (Figure 5). Treatment of U251 or U87 GBM cells with 100 µM DCPIB for one or
two days did not alter the relative phosphorylation of Akt or ULK (p-Akt/t-Akt and p-ULK/t-ULK,
respectively, Figure 5A–E). Likewise, the phosphorylation was not changed three days after LRRC8A
siRNA transfection, when LRRC8A protein levels were significantly reduced (Figure 5H,J). Collectively,
the results suggest that neither pharmacological VRAC inhibition nor siRNA-mediated downregulation
of LRRC8A affected PI3K/Akt signaling.
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Figure 5. Treatment with DCPIB or siRNA-mediated knockdown of LRRC8A have no effects on
PI3K/Akt signaling. (A) Western blot of GBM cells treated with DCPIB (100 µM) at day 1 or day 2
for total amount and phosphorylated forms of Akt and ULK. GAPDH used as loading control. A
representative blot of three independent experiments is shown. Analysis of the p-Akt/t-Akt (B,D)
and p-ULK/t-ULK (C,E) ratio for U251 (B,C) and U87 (D,E) cells. (F) Western blotting of GBM cells
for total amount and phosphorylated forms of Akt and ULK 72 h after siRNA transfection. For
LRRC8A, the same samples were used as in Figure 4A and 4B. GAPDH used as loading control. A
representative blot of three independent experiments is shown. Analysis of the p-Akt/t-Akt (G,I) and
p-ULK/t-ULK (H,J) ratio for U251 (G,H) and U87 (I,J) cells. All data are presented as mean ± SD of
n = 3 independent experiments.
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3. Discussion
The volume-regulated anion channel (VRAC) is ubiquitously expressed in vertebrate cells [1,2,29]
and contributes to regulatory volume decrease upon osmotic cell swelling. As the extracellular
osmolarity is usually kept constant, most animal cells rarely experience extracellular hypo-osmolarity
under normal conditions. Thus, the VRAC is thought to play roles in other physiological processes by
its impact on cellular volume, such as during cell proliferation and migration [2,26,54].
Several studies reported an impairment of proliferation and/or migration of various cell lines in
the presence of VRAC inhibitors [24,25,28–38]. However, the available VRAC inhibitors display little
selectivity and often also inhibit other anion channels [55,56], or as in the case of the potent and relatively
selective VRAC blocker DCPIB [57] even modulate potassium channels [58,59]. The identification of
LRRC8 proteins as essential VRAC components [4,5] enabled investigating physiological functions
of VRAC by molecular biological tools. Using this approach, siRNA-mediated downregulation of
the essential VRAC subunit LRRC8A reduced proliferation of primary glioblastoma and U251 GBM
cells [40], and knockdown of LRRC8A in the colorectal cancer cell line HCT116 was shown to impair
cell migration in a wound healing assay [41].
In contrast, using both pharmacological and molecular biological approaches we found no
evidence for a role of VRAC in the proliferation or migration in a range of cell lines including
non-differentiated C2C12 myoblasts, colorectal cancer HCT116 cells, and GBM cell lines U251 and
U87. Whereas, inhibition of VRAC with DCPIB (at higher concentrations than required to inhibit
VRAC currents) in these latter GBM cell lines [28] and siRNA-mediated LRRC8A knockdown in U251
cells [40] was reported to reduce cell viability and proliferation, however, we did not observe such effect
by either treatment in these cell lines. A possible explanation for the apparently conflicting results may
be that we measured the increasing confluence of the proliferating cells, while in the previous studies
the cells’ metabolic activity was measured using the MTT assay. Measuring the cell number directly
with a Coulter counter, the most efficient siRNA showed much less reduction in cell proliferation as
compared with the MTT assay [40]. The reportedly reduced migration of GBM cells in the presence
of DCPIB, which we did not observe in our study, may be explained by their impaired proliferation
also during the wound healing assay [28]. The discrepancy between our finding, on the one hand,
that knockout of LRRC8A or all LRRC8 members did not diminish HCT116 cell migration, and on
the other hand, the previous report of slowed HCT116 migration upon siRNA-mediated LRRC8A
knockdown [41] is unlikely due to upregulation of compensatory mechanisms in our case, since the
migration speed was also unaffected upon acute pharmacological VRAC inactivation.
Other studies corroborate the notion that VRAC is dispensable for cell proliferation. The flavonoid
Dh-morin suppressed VRAC currents but did not reduce proliferation of HUVEC cells [43], and siRNA
against LRRC8A did not affect the proliferation rate in HeLa cells [42]. The DCPIB treatment even
inhibited the antiproliferative effect of cardiac glycosides that correlated with an increase in VRAC
activity in HT-29 cells [44].
The slowed proliferation and migration of U251 GBM cells was related to a reduction of
PI3K/Akt/mTor signaling in the presence of 100 µM DCPIB for 24 or 48 h [28]. In our study, we were
not able to detect differences in the basal phosphorylation state of Akt1 in U251 or U87 GBM cells upon
treatment with 100 µM DCPIB for one or two days. Neither did we find a reduced phosphorylation of
the mTOR substrate ULK. In addition, Akt signaling was not altered by siRNA-mediated LRRC8A
knockdown. This was consistent with the previously reported normal anti-CD3-mediated activation
of Akt1 in thymocytes from LRRC8A-deficient mice [60]. In adipocytes, LRRC8A was reported to be
involved in the regulation of insulin-stimulated Akt2 signaling [61]. However, no effect on Akt1 was
detected upon LRRC8A deletion in that study [61], which was in agreement with our findings for
glioblastoma cells.
In summary, our study demonstrates that LRRC8/VRAC is not crucially involved in general cell
proliferation. Its indispensability for cell migration in the wound healing assay does not rule out a
role for VRAC in constricted environments where directed osmotic water flux has been shown to
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drive cellular locomotion [23]. The VRAC inhibitor NPPB was shown to impair this process of cell
invasion [62]. Apart from VRAC, other chloride channels may contribute, such as the calcium-activated
chloride channel TMEM16A [63]. Future work is required to clarify the potentially cell-type-specific
roles of the different types of ion channels under more physiological conditions in cell migration
and invasion.
4. Materials and Methods
4.1. Reagents
Mitomycin C was purchased from Sigma-Aldrich (Taufkirchen, Germany). 5-nitro-2-(3-
phenylpropylamino)benzoic acid (NPPB) and 4-[(2-Butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-
oxo-1H-inden-5-yl)oxy]butanoic acid (DCPIB) were purchased from Tocris Bioscience (Avonmouth,
Bristol, UK). Carbenoxolone (CBX) and fibronectin were purchased from Sigma-Aldrich. Dimethyl
sulfoxide (DMSO) was purchased from PAN-Biotech (Aidenbach, Germany).
4.2. Cell Culture
Wild-type and LRRC8 knockout HCT116 cell lines (clone 3F8 for LRRC8A-/-) [4], kindly provided
by T. J. Jentsch (FMP and MDC, Berlin, Germany), were maintained in McCoy’s 5A Medium (GIBCO)
with 10% fetal bovine serum (FBS) at 37 ◦C in the presence of antibiotics in a humidified atmosphere
with 5% CO2. U251 and U87 cells were kindly provided by U. Stein and H. Kettenmann (both MDC,
Berlin, Germany), respectively, and authenticated using highly-polymorphic short tandem repeat
loci (Microsynt, Balgach, Switzerland). C2C12 cells, kindly provided by P. Knaus (Freie Universität
Berlin, country), U251 and U87 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM)
(Sigma-Aldrich) supplemented with 10% FBS, 100 U/mL penicillin, and 100 µg/mL streptomycin in a
37 ◦C, 5% CO2 humidified chamber.
4.3. siRNA Transfection
U251 and U87 cells were plated in 6-well cell culture plates (1.5 × 105 cells per well) 1 day prior
to transfection. The cell culture medium was removed and cells were washed with the serum-free
Opti-MEM, then transfected with siRNA against LRRC8A (Lrrc8a siRNA: sense-CCU UGU AAG UGG
GUC ACC ATT) (ThermoFisher Scientific, Darmstadt, Germany) #s109501 at a concentration of 15 nM
using lipofectamine RNAiMax transfecting agent (ThermoFisher Scientific). A nontargeting, scrambled
siRNA (ThermoFisher Scientific, 4390844) was used as a negative control. For the proliferation assay,
cells were grown for a further 48 h before seeding into a 96-well plate. For the migration assay, cells
were grown for a further 30–42 h post-transfection, then plated in a 96-well ImageLock™ tissue culture
plate. Wounds were created 48 h after siRNA transfection.
4.4. Cell Proliferation and Migration Assays
To assess cell proliferation, 5000 cells (10,000 cells in the case of HCT116) per well were seeded
into a 96-well plate and placed into the IncuCyte live-cell analysis system. Before scanning, the plate
was allowed to acclimatize for 30 min. Cell proliferation was monitored by using the IncuCyte system
(Sartorius, Göttingen, Germany) to capture phase contrast images every 2 h during constant incubation
at 37 ◦C in a humidified atmosphere with 5% CO2.
To assess cell migration, 2–8 × 104 cells (depending on cell type) per well were seeded into a
96-well ImageLock™ plate (Essen BioScience 4379, Sartorius, Göttingen, Germany) and incubated for
4–16 h at 37 ◦C in a humidified atmosphere with 5% CO2 before replacing the medium with culture
medium supplemented with 5 µg/mL mitomycin C. Mitomycin C was applied during the following
steps, if not specified otherwise, to inhibit cell proliferation so that this process would not distort our
results on cell migration. After 2 h, wounds were created in all wells of the 96-well ImageLock™ plate
with the WoundMaker™ (Sartorius, Göttingen, Germany). After gently washing the wells twice with
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culture medium, 100 µL of medium containing additional drugs (CBX, DCPIB, NPPB, or vehicle DMSO
when appropriate) were applied to each well. NPPB and DCPIB were dissolved in DMSO, CBX in
water. Cell migration was monitored by phase contrast imaging with an IncuCyte Zoom microscope,
acquiring an image every 2 h during constant incubation at 37 ◦C in a humidified atmosphere with
5% CO2. The IncuCyte Zoom image analysis software (Sartorius, Göttingen, Germany) was used to
detect cell edges automatically and to generate an overlay mask for wound width calculation. For the
migration assay with HCT116, the 96-well ImageLock™ plates were coated with fibronectin prior to
cell seeding.
4.5. Antibodies and Western Blotting
For Western blotting, equivalent amounts of sample protein were separated by 10% SDS-PAGE
and transferred to nitrocellulose membrane (Macherey Nagel, Düren, Germany). After blocking
with 5% BSA in TBS-T (20 mM Tris pH 7.6, 150 mM NaCl and 0.02% Tween-20), the membrane was
immunoblotted with primary antibodies overnight at 4 ◦C. The following primary antibodies were
used: rabbit anti-LRRC8A (1 µg/mL, [4] kindly supplied by T. J. Jentsch); rabbit anti-p-ULK (1:1000, Cell
Signaling, Frankfurt am Main, Germany; #14202); rabbit anti-ULK (1:1000, cell signaling, #8054); rabbit
anti-p-AktSer473 (1:1000, Cell Signaling; #4060); rabbit anti-Aktpan (1:1000, Cell Signaling; #4685); and
rabbit anti-GAPDH (1:2500, Cell Signaling; #2118) antibodies. The corresponding peroxidase-labeled
secondary antibody (1:10,000, Jackson ImmunoResearch, Ely, UK) was used. Signals were detected
using an enhanced chemiluminescence reagent (HRP juice; PJK GmbH, Kleinblittersdorf, Germany)
and a ChemiSmart5000 digital imaging system (Vilber-Lourmat, Collégien, France). Densitometrical
quantification was performed with the Fiji software [64].
4.6. Generation of C2C12 LRRC8A Knockout Cell Lines Using CRISPR/Cas9 Technology
To create LRRC8A knockout C2C12 cells using the CRISPR/Cas9 technology, the targeting sgRNA
sequences (5′-GCCCCGGAAGGAGTCGTTGCAGG-3′) was cloned into the px459-V.2 vector and
transfected into C2C12 cells. Two days post-transfection, transfected cells were selected by treatment
with 10 µg/mL puromycin for two days before single clone expansion by dilution to statistically 0.5 cells
per well in 96-well format. Monoclonal cell lines were expanded and tested for sequence alterations
using target-site-specific PCR with primers 5′-CATGTATGTCTCACTACACCTAACTTGTAG-3′ and
5′-CCAGGAAGATGAGGGTGTGCA-3′ on genomic DNA followed by Sanger sequencing.
4.7. Statistical Analysis
Proliferation and migration were quantified with the IncuCyte Zoom image analysis software by
measuring cell confluence and wound width over time, respectively. The software OriginPro 2017
(OriginLab, Northampton, MA, USA) was used for statistical analyses. All data are presented as the
mean values ± SD For comparisons between two groups, p-values were determined using Student’s
t-test and are indicated according to convention: * p < 0.05, ** p < 0.01 and *** p < 0.001.
Supplementary Materials: Supplementary Materials can be found at http://www.mdpi.com/1422-0067/20/11/
2663/s1.
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